CN105120865A - 蕈毒碱激动剂 - Google Patents

蕈毒碱激动剂 Download PDF

Info

Publication number
CN105120865A
CN105120865A CN201480015640.8A CN201480015640A CN105120865A CN 105120865 A CN105120865 A CN 105120865A CN 201480015640 A CN201480015640 A CN 201480015640A CN 105120865 A CN105120865 A CN 105120865A
Authority
CN
China
Prior art keywords
compound
group
disease
methyl
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480015640.8A
Other languages
English (en)
Chinese (zh)
Inventor
E·S·伯斯坦
于尔根·埃斯基尔德森
R·奥尔森
劳伦·M·鲁弗斯
拉里·A·惠勒
丹尼尔·W·吉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Publication of CN105120865A publication Critical patent/CN105120865A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Emergency Medicine (AREA)
CN201480015640.8A 2013-03-15 2014-03-14 蕈毒碱激动剂 Pending CN105120865A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790364P 2013-03-15 2013-03-15
US61/790,364 2013-03-15
PCT/US2014/026998 WO2014152144A1 (en) 2013-03-15 2014-03-14 Muscarinic agonists

Publications (1)

Publication Number Publication Date
CN105120865A true CN105120865A (zh) 2015-12-02

Family

ID=50439523

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480015640.8A Pending CN105120865A (zh) 2013-03-15 2014-03-14 蕈毒碱激动剂

Country Status (13)

Country Link
US (1) US9670209B2 (https=)
EP (1) EP2976079A1 (https=)
JP (1) JP2016513677A (https=)
KR (1) KR20150143439A (https=)
CN (1) CN105120865A (https=)
AU (1) AU2014240139A1 (https=)
BR (1) BR112015021271A2 (https=)
CA (1) CA2903276A1 (https=)
IL (1) IL241001A0 (https=)
MX (1) MX2015012043A (https=)
RU (1) RU2015144155A (https=)
TW (1) TW201446761A (https=)
WO (1) WO2014152144A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152144A1 (en) 2013-03-15 2014-09-25 Acadia Pharmaceuticals Inc. Muscarinic agonists
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
EP3795563B1 (en) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087158A2 (en) * 2003-03-28 2004-10-14 Acadia Pharmaceuticals Inc. Muscarinic m1 receptor agonists for pain management
EP1535912A1 (en) * 2000-04-28 2005-06-01 Arcadia Pharmaceuticals Inc. Muscarinic agonists
US20050209226A1 (en) * 2001-12-28 2005-09-22 Niels Skjaerbaek Tetrahydroquinoline analogues as muscarinic agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
JPH10152470A (ja) * 1996-09-25 1998-06-09 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
CN1249051C (zh) 2000-04-28 2006-04-05 阿卡蒂亚药品公司 毒蕈碱性激动剂
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
WO2014152144A1 (en) 2013-03-15 2014-09-25 Acadia Pharmaceuticals Inc. Muscarinic agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1535912A1 (en) * 2000-04-28 2005-06-01 Arcadia Pharmaceuticals Inc. Muscarinic agonists
US20050209226A1 (en) * 2001-12-28 2005-09-22 Niels Skjaerbaek Tetrahydroquinoline analogues as muscarinic agonists
WO2004087158A2 (en) * 2003-03-28 2004-10-14 Acadia Pharmaceuticals Inc. Muscarinic m1 receptor agonists for pain management

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEINRICH J N ET AL: "Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 *
KENNETH J.BROADLEY ET AL: "Muscarinic Receptor Agonists and Antagonists", 《MOLECULES》 *

Also Published As

Publication number Publication date
RU2015144155A (ru) 2017-04-24
BR112015021271A2 (pt) 2017-08-22
US20160039819A1 (en) 2016-02-11
JP2016513677A (ja) 2016-05-16
TW201446761A (zh) 2014-12-16
MX2015012043A (es) 2016-03-17
WO2014152144A1 (en) 2014-09-25
CA2903276A1 (en) 2014-09-25
KR20150143439A (ko) 2015-12-23
AU2014240139A1 (en) 2015-09-17
US9670209B2 (en) 2017-06-06
EP2976079A1 (en) 2016-01-27
IL241001A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
KR102021651B1 (ko) 퓨리논 유도체 염산염
CN102838546B (zh) 作为5-ht2a血清素受体调节剂用于治疗与其相关病症的吡唑衍生物
TWI288748B (en) Quinazoline derivatives
US7470686B2 (en) Method of inhibiting the expression and/or the activity of JNK
CN109563047A (zh) 含有硅原子的依伐卡托类似物
SA518391033B1 (ar) مركبات أمينو ترايازول به استبدال مفيدة باعتبارها مثبطات إنزيم كيتيناز بشري
CN103224497A (zh) 蛋白激酶抑制剂
CN103012378A (zh) 作为5-ht2a血清素受体调节剂适用于治疗与其相关的病症的3-苯基-吡唑衍生物
CN105899490A (zh) 嘧啶fgfr4抑制剂
CN101282972A (zh) 作为p2x3拮抗剂的哌啶和哌嗪衍生物
CN104230911A (zh) 作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物
KR102723194B1 (ko) Cftr 조절제 및 이의 사용 방법
KR102733897B1 (ko) Cftr 조절제 및 이의 사용방법
WO2021164746A1 (zh) 取代芳基类化合物
CN104922117A (zh) 用于治疗月经前病症的β-内酰氨基链烷酸
IL303382A (en) Heteroaryl-acetylenes, pharmaceutical compositions thereof, and their therapeutic applications
JP2002502419A (ja) ５−ｈｔ▲下１ｆ▼アゴニストとして有用なカルボキサミド
US20260049071A1 (en) Protein tyrosine kinase inhibitor and medical use thereof
CN105120865A (zh) 蕈毒碱激动剂
WO2021045159A1 (ja) 併用医薬による糖尿病の治療又は予防方法
JP7336017B2 (ja) ホウ素含有ｒｈｏキナーゼ阻害剤
KR20200013702A (ko) α7니코틴성 아세틸콜린 수용체의 리간드 화합물 및 그 응용
KR20250043398A (ko) 신규 7-치환 인돌 설폰아미드 유도체
KR20250042748A (ko) 신규 7-치환 인돌 설폰아미드 유도체
CN102781914A (zh) 吲哚衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151211

Address after: American California

Applicant after: Acadia Pharmaceutical, Inc.

Applicant after: Allergan

Address before: American California

Applicant before: Acadia Pharmaceutical, Inc.

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20180622